The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and mitigate supply chain vulnerabilities, including collaborating with the private sector to develop and implement programs to assess and incentivize resiliency in manufacturer and hospital purchasing behavior. The paper focuses on generic sterile injectable medicines used in inpatient settings, citing their importance and relative risk of supply disruptions.

Related News Articles

Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…
Headline
In a statement submitted to the Senate Finance Committee Dec. 5 for a hearing on drug shortages and potential health policy solutions, AHA reiterated its…
Headline
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of…
Headline
The House Energy and Commerce Committee held a hearing on legislative proposals to prevent and respond to generic drug shortages. In comments submitted…